Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash from Operations: 2020-2021

Historic Cash from Operations for Design Therapeutics (DSGN) over the last 2 years, with Dec 2021 value amounting to -$9.2 million.

  • Design Therapeutics' Cash from Operations fell 224.44% to -$9.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$29.4 million, marking a year-over-year decrease of 238.87%. This contributed to the annual value of -$43.1 million for FY2024, which is 26.39% up from last year.
  • Design Therapeutics' Cash from Operations amounted to -$9.2 million in Q4 2021, which was down 13.02% from -$8.2 million recorded in Q3 2021.
  • Over the past 5 years, Design Therapeutics' Cash from Operations peaked at -$1.3 million during Q2 2020, and registered a low of -$9.2 million during Q4 2021.
  • Its 2-year average for Cash from Operations is -$4.8 million, with a median of -$3.3 million in 2020.
  • Data for Design Therapeutics' Cash from Operations shows a maximum YoY slumped of 534.20% (in 2021) over the last 5 years.
  • Quarterly analysis of 2 years shows Design Therapeutics' Cash from Operations stood at -$2.8 million in 2020, then plummeted by 224.44% to -$9.2 million in 2021.
  • Its last three reported values are -$9.2 million in Q4 2021, -$8.2 million for Q3 2021, and -$8.3 million during Q2 2021.